CoChat

Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

The tumor microenvironment is composed of cellular and stromal components such as tumor cells, mesenchymal cells, immune cells, cancer associated fibroblasts and the supporting extracellular matrix. The tumor microenvironment provides crucial support for growth and progression of tumor cells and affects tumor response to therapeutic interventions. To better understand tumor biology and to develop effective cancer therapeutic agents it is important to develop preclinical platforms that can faithfully recapitulate the tumor microenvironment and the complex interaction between the tumor and its surrounding stromal elements. Drug studies performed in vitro with conventional two-dimensional cancer cell line models do not optimally represent clinical drug response as they lack true tumor heterogeneity and are often performed in static culture conditions lacking stromal tumor components that significantly influence the metabolic activity and proliferation of cells. Recent microfluidic approaches aim to overcome such obstacles with the use of cell lines derived in artificial three-dimensional supportive gels or micro-chambers. However, absence of a true tumor microenvironment and full interstitial flow, leads to less than optimal evaluation of tumor response to drug treatment. Here we report a continuous perfusion microfluidic device coupled with microscopy and image analysis for the assessment of drug effects on intact fresh tumor tissue. We have demonstrated that fine needle aspirate biopsies obtained from patient-derived xenograft models of adenocarcinoma of the lung can successfully be analyzed for their response to ex vivo drug treatment within this biopsy trapping microfluidic device, wherein a protein kinase C inhibitor, staurosporine, was used to assess tumor cell death as a proof of principle. This approach has the potential to study tumor tissue within its intact microenvironment to better understand tumor response to drug treatments and eventually to choose the most effective drug and drug combination for individual patients in a cost effective and timely manner.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0169797

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Microfluidic device design. (A) Exploded view of the device showing the main body made from PDMS containing the 1 mm diameter inlet and outlets punched for each of the 10 channels. The main body is then sealed to a 25 x 75 mm glass slide by plasma gas treatment. Tubing is inserted into each of the inlet and outlets of the device. (B) Fully assembled PDMS prototype. (C) Solid Works rendering of a channel in the device showing the central post arrangement used to trap each FNAB tissue sample. The channel is 10 mm long, 600 μm wide and 125 μm in height. Each post is 150 μm long, 75 μm wide and 125 μm in height.
Fig 1 Microfluidic device design. (A) Exploded view of the device showing the main body made from PDMS containing the 1 mm diameter inlet and outlets punched for each of the 10 channels. The main body is then sealed to a 25 x 75 mm glass slide by plasma gas treatment. Tubing is inserted into each of the inlet and outlets of the device. (B) Fully assembled PDMS prototype. (C) Solid Works rendering of a channel in the device showing the central post arrangement used to trap each FNAB tissue sample. The channel is 10 mm long, 600 μm wide and 125 μm in height. Each post is 150 μm long, 75 μm wide and 125 μm in height.CC BY · PubMed Central
Fig 2 Assessment of small molecule drug perfusion in a tumor FNA fragment using Doxorubicin HCL. (A) Drug perfusion after an 8-hour period showing distribution of drug indicated by green fluorescent intensity spatially similar throughout the FNAB tissue sample. (B) Drug perfusion after a 24-hour period showing intensity peaks spatially similar throughout the FNAB tissue sample and the formation of apoptotic bodies.
Fig 2 Assessment of small molecule drug perfusion in a tumor FNA fragment using Doxorubicin HCL. (A) Drug perfusion after an 8-hour period showing distribution of drug indicated by green fluorescent intensity spatially similar throughout the FNAB tissue sample. (B) Drug perfusion after a 24-hour period showing intensity peaks spatially similar throughout the FNAB tissue sample and the formation of apoptotic bodies.CC BY · PubMed Central
Fig 3 Evaluation of antibody perfusion through the tumor FNAB on device. (A) 10x Phase contrast image of FNAB sample in trap of device and 10x fluorescent z-axis images (z5, z7, z9, z11) 24 hours post the staining procedure using isotype control antibodies for both EpCAM (red-Cy5) and CD44 (green-FITC). (B) 10x Phase contrast image of FNAB sample in trap of device and 10x fluorescent z-axis images (z5, z7, z9, z11) 24 hours post the staining procedure using EpCAM (red-Cy5) and CD44 (green-FITC).
Fig 3 Evaluation of antibody perfusion through the tumor FNAB on device. (A) 10x Phase contrast image of FNAB sample in trap of device and 10x fluorescent z-axis images (z5, z7, z9, z11) 24 hours post the staining procedure using isotype control antibodies for both EpCAM (red-Cy5) and CD44 (green-FITC). (B) 10x Phase contrast image of FNAB sample in trap of device and 10x fluorescent z-axis images (z5, z7, z9, z11) 24 hours post the staining procedure using EpCAM (red-Cy5) and CD44 (green-FITC).CC BY · PubMed Central
Fig 4 Comparison of the calculated viability index of the tumor FNAB samples during 5 days of treatment. (A) Comparison of the mean averaged VI of negative control group and staurosporine treated group from the baseline over the 5 day exposure period with n = 18 within each group. The difference in means between each treatment group was statistically significant, except for the baseline. (B.1, B.3) A 3-dimensional view of a representative FNAB sample from the negative control group at day 1 and day 5 respectively. (B.2, B.4) Histogram of the relative intensity values across the negative control FNAB samples for day 1 and day 5, respectively. (C.1, C.3) A 3-dimensional view of a representative FNAB sample from the 50 μM staurosporine treated group at day 1 and day 5 respectively. (C.2, C.4) Histogram of the relative intensity values across the 50 μM staurosporine treated FNAB samples for day 1 and day 5 respectively.
Fig 4 Comparison of the calculated viability index of the tumor FNAB samples during 5 days of treatment. (A) Comparison of the mean averaged VI of negative control group and staurosporine treated group from the baseline over the 5 day exposure period with n = 18 within each group. The difference in means between each treatment group was statistically significant, except for the baseline. (B.1, B.3) A 3-dimensional view of a representative FNAB sample from the negative control group at day 1 and day 5 respectively. (B.2, B.4) Histogram of the relative intensity values across the negative control FNAB samples for day 1 and day 5, respectively. (C.1, C.3) A 3-dimensional view of a representative FNAB sample from the 50 μM staurosporine treated group at day 1 and day 5 respectively. (C.2, C.4) Histogram of the relative intensity values across the 50 μM staurosporine treated FNAB samples for day 1 and day 5 respectively.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 37

Metadata

Authors
Holton, A. B., Sinatra, F. L., Kreahling, J., Conway, A. J., Landis, D. A., & Altiok, S.
Affiliations
  • University of South Florida (US)
  • Moffitt Cancer Center (US)
Corresponding author
Altiok, Soner
Venue
PLOS ONE
Published
2017-01-13
Volume
12
Issue
1
Pages
e0169797
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2579680847
Cited by
35
References
65
Citations by year
2025: 3 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 9
FWCI
2.09
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Charles Stark Draper Laboratory
  • H. Lee Moffitt Cancer Center and Research Institute
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
tumor microenvironment, microfluidic perfusion, patient-derived xenografts, lung adenocarcinoma, staurosporine, PKC inhibitors, cancer cell death, tumor stroma, preclinical drug testing, precision oncology
MeSH terms
Animals, Antibiotics, Antineoplastic, Antibodies, Monoclonal, Biopsy, Doxorubicin, Enzyme Inhibitors, Female, Humans, Mice, Hairless, Neoplasms, Tumor Cells, Cultured, Mice, SCID, Apoptosis, Cell Culture Techniques, Staurosporine, Xenograft Model Antitumor Assays, Microfluidic Analytical Techniques, Cell Proliferation, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment. https://app.cochat.ai/papers/10.1371/journal.pone.0169797
The paper
Holton, A. B., Sinatra, F. L., Kreahling, J., Conway, A. J., Landis, D. A., & Altiok, S. (2017). Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment. PLOS ONE. https://doi.org/10.1371/journal.pone.0169797

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.